Many of these deaths are due to rapid onset of chemoresistant disease in triple negative breast cancer (TNBC) cases, which are devoid of estrogen receptor (ERα-), progesterone receptor (PR-) and human epidermal growth factor receptor (HER2-) amplification. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.